Skip to main content
    I

    ImmuCell Corporation (ICCC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.56
    -0.19 (-1.77%)

    Market Cap: $97.63M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    88%(7/8)
    Avg Surprise
    +26.88%
    Streak
    6 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Aug 13
    		$0.20N/AN/ABeat+233.3%
    Mar 26
    Reported May 14
    		$0.21N/AN/ABeat+33.2%
    Dec 25
    Reported Mar 4
    		$-0.31N/AN/ABeat-646.7%
    Sep 25
    Reported Nov 13
    		$-0.02N/AN/ABeat+76.7%
    Jun 25
    Reported Aug 14
    		$0.06N/AN/ABeat+130.6%
    Mar 25
    Reported May 14
    		$0.16N/AN/ABeat+385.1%
    Dec 24
    Reported Feb 25
    		$0.06N/AN/ABeat+139.2%
    Sep 24
    Reported Nov 13
    		$-0.09N/AN/ABeat+28.4%
    Jun 24
    Reported Aug 13
    		$-0.20N/AN/ABeat-208.9%
    Mar 24
    Reported May 14
    		$-0.06N/AN/ABeat+81.2%
    Dec 23
    Reported Feb 27
    		$-0.15N/AN/ABeat+54.0%
    Sep 23
    Reported Nov 13
    		$-0.12N/AN/ABeat-41.8%
    Jun 23
    Reported Aug 10
    		$0.18N/AN/ABeat+300.0%
    Mar 23
    Reported May 11
    		$-0.30N/AN/ABeat-433.3%
    Dec 22
    Reported Feb 21
    		$-0.32N/AN/ABeat-3100.0%
    Sep 22
    Reported Nov 21
    		$-0.08N/AN/ABeat-523.0%
    Jun 22
    Reported Aug 11
    		$-0.09N/AN/ABeat-550.0%
    Mar 22
    Reported May 12
    		$0.09N/AN/ABeat+250.0%
    Dec 21
    Reported Feb 22
    		$-0.01$-0.01+0.00%Beat-133.3%
    Sep 21
    Reported Nov 15
    		$0.02$0.02+0.00%Beat+150.0%
    Jun 21
    Reported Aug 12
    		$0.02$0.02+0.00%Beat+118.2%
    Mar 21
    Reported May 13
    		$-0.06$-0.06+0.00%Beat-200.0%
    Dec 20
    Reported Feb 22
    		$0.03$-0.04+175.00%Beat+150.0%
    Sep 20
    Reported Nov 12
    		$-0.04$-0.08+50.00%Beat+42.9%
    Jun 20
    Reported Aug 12
    		$-0.11$-0.10-10.00%Miss-22.2%
    Mar 20
    Reported May 13
    		$-0.02$-0.02+0.00%Beat-166.7%
    Dec 19
    Reported Feb 18
    		$-0.06N/AN/ABeat+68.4%
    Sep 19
    Reported Nov 11
    		$-0.07N/AN/ABeat-40.0%
    Jun 19
    Reported Aug 12
    		$-0.09N/AN/ABeat+40.0%
    Mar 19
    Reported May 13
    		$0.03N/AN/ABeat+175.0%
    Dec 18
    Reported Feb 13
    		$-0.19N/AN/ABeat-280.0%
    Sep 18
    Reported Nov 13
    		$-0.05N/AN/ABeat+28.6%
    Jun 18
    Reported Aug 13
    		$-0.15N/AN/ABeat-200.0%
    Mar 18
    Reported May 14
    		$-0.04N/AN/ABeat-133.3%
    Dec 17
    Reported Feb 8
    		$-0.05N/AN/ABeat-906.5%
    Sep 17
    Reported Nov 13
    		$-0.07N/AN/ABeat-
    Jun 17
    Reported Aug 14
    		$-0.05N/AN/ABeat-
    Mar 17
    Reported May 11
    		$0.12N/AN/ABeat-
    Dec 16
    Reported Feb 9
    		$0.01N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio132.50EV/EBITDA29.04x
    Price/FCF22.71xFCF Yield4.40%
    Profitability
    Profit Margin2.57%Operating Margin26.90%
    ROE2.57%ROIC1.98%
    Financial Health
    Debt/Equity0.26xInterest CoverageN/A
    Current Ratio4.75xQuick Ratio2.71x
    Trading Statistics
    Beta0.57Avg Volume13.21K
    52-Week High$12.1052-Week Low$4.52

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$10.04
    SMA 20$9.98
    SMA 50$10.06
    SMA 200$8.64
    EMA 10$10.18
    EMA 20$10.05
    EMA 50$10.05
    EMA 200$8.95

    MACD

    Line: 0.10Signal: -0.01Hist: 0.11

    ADX

    ADX: 20.6+DI: 28.2-DI: 15.2

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down16.0
    PSAR$9.60

    Bollinger Bands

    Upper Band$10.66
    Lower Band$9.30
    %B Position1370%(Upper)
    Band Width0.92

    RSI (14-Day)

    Neutral
    60.7

    Momentum Oscillators

    Stoch %K90.3
    Stoch %D69.7
    Williams %R-24.4
    ROC (10d)10.0%
    Momentum0.96
    CCI (20d)208.7
    MFI (14d)54.7

    Volatility Measures

    ATR (14d)$0.33(3.1%)
    StdDev (20d)0.34
    Hist Vol49.8%(High)

    Volume Flow

    VWAP$10.63
    OBV594.1K
    AD Line-796.8K
    CMF (20d)0.159

    Volume Metrics

    Avg Vol (20d)11.3K
    Vol Ratio0.9x
    VWMA (20d)$10.10

    Pivot Points

    R3$11.17
    R2$10.98
    R1$10.87
    Pivot Point$10.68
    S1$10.57
    S2$10.38
    S3$10.27

    Advanced Oscillators

    TSI9.24
    Ultimate Osc62.4
    KST10.28

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$7.19M$10.36M$7.63M$5.51M$6.44M$8.07M$7.75M$6.01M$5.47M$7.26M$5.10M$5.40M
    Cost of Revenue$4.75M$5.70M$4.72M$3.14M$3.63M$4.71M$4.92M$4.43M$4.24M$4.96M$3.84M$4.13M
    Gross Profit$2.44M$4.66M$2.91M$2.36M$2.82M$3.35M$2.83M$1.58M$1.23M$2.30M$1.26M$1.27M
    Operating Expenses$502,288$2.69M$2.97M$2.34M$2.25M$2.24M$2.21M$2.16M$2.62M$2.60M$2.26M$2.45M
    R&D$119,652$317,688$758,864$694,311$831,858$756,847$819,394$786,136$1.03M$1.26M$1.07M$1.12M
    SG&A$1.27M$1.14M$1.13M$729,421$720,418$622,843$554,710$528,267$601,634$531,938$523,268$514,952
    Operating Income$1.93M$1.97M$-57,956$20,075$569,562$1.12M$621,394$-574,894$-1,386,607$-300,052$-1,003,498$-1,184,046
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$54,328$15,187$2.79M$155,367$65,778$0$100,803$125,456$143,679$136,476$134,985$0
    Income Before Tax$1.88M$1.95M$-2,845,836$-135,292$503,784$1.45M$520,591$-700,350$-1,530,286$-436,528$-1,138,483$-939,771
    Income Tax Expense$45,950$12,522$3,306$4,456$1,904$1,904$6,036$1,340$1,340$1,340$1,348$229
    Net Income$1.83M$1.94M$-2,849,142$-139,748$501,880$1.45M$514,555$-701,690$-1,531,626$-437,868$-1,139,831$-940,000
    EBITDA$2.35M$2.49M$-2,136,364$573,375$1.18M$2.14M$1.21M$-14,423$-848,521$240,972$-453,504$-230,673
    EBIT$1.88M$1.95M$-2,845,836$-135,292$503,784$1.45M$520,591$-700,350$-1,530,286$-436,528$-1,138,483$-939,771
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ICCC

    News

    ImmuCell reports Q3 2026 sales up 46% to $8.0M; nine-month sales $25.6M

    ImmuCell (ICCC) reported preliminary Q3 2026 sales of $8.0 million, marking a 46.0% increase year-over-year, with domestic sales up 29.2% to $6.9 million. Nine-month sales reached $25.6 million...

    TradingView•10/13/26•Bullish

    ImmuCell Reports 46% Increase in Third-Quarter 2026 Sales

    ImmuCell (ICCC) announced a 46% increase in preliminary, unaudited total sales for the third quarter of 2026, reaching $8.0 million. For the first nine months of 2026...

    Quiver Quantitative•10/13/26•Bullish

    ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results

    ImmuCell Corporation reported a 46% increase in product sales for the third quarter of 2026, reaching $8.0 million, and a 27.8% increase for the nine months ended September 30, 2026...

    The Manila Times•10/12/26•Bullish

    ImmuCell reports 46% Q3 sales increase to $8.0 million

    ImmuCell Corporation announced a 46.0% increase in preliminary third-quarter sales, reaching $8.0 million, with domestic sales up 29.2% year-over-year. For the first nine months of 2026...

    Investing.com•10/12/26•Bullish

    ImmuCell Reports Preliminary Third Quarter 2026 Sales Up 46% to $8.0 Million

    ImmuCell Corporation announced preliminary unaudited sales of $8.0 million for the third quarter of 2026, marking a 46% increase year-over-year...

    Quiver Quantitative•10/12/26•Bullish

    ICCC Valuation and Fair Value

    P/E
    132.5x
    EV/EBITDA
    29.0x
    P/FCF
    22.7x
    PEG
    0.0x
    P/B
    3.1x
    See GNG's fair value

    ICCC Profitability: Margins, ROIC and FCF

    Gross margin
    40.3%
    Operating margin
    26.9%
    Net margin
    2.6%
    ROIC
    2.0%
    ROE
    2.6%
    FCF margin
    13.7%
    FCF yield
    4.4%

    ICCC Competitors

    CompanyTicker
    Coya Therapeutics, Inc. Common StockCOYA
    Milestone Pharmaceuticals IncMIST
    PolyPidPYPD
    Rani Therapeutics Holdings IncRANI
    The Joint CorpJYNT
    Pmv Pharmaceuticals IncPMVP
    Humacyte IncHUMA
    Anixa Biosciences IncANIX

    Sector: Healthcare

    ICCC Bull Case vs Bear Case

    Bull case

    • ICCC grew quarterly revenue 11.5% year over year.

    Bear case

    • ICCC trades at 132.5x trailing earnings.
    • ICCC beat EPS estimates in 25.0% of its last 8 reported quarters.

    ICCC Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    26.9%

    Frequently Asked Questions About ICCC

    Does ICCC pay dividends?

    ImmuCell Corporation (ICCC) does not currently pay a regular dividend.

    What is ICCC's P/E ratio?

    ImmuCell Corporation has a price-to-earnings (P/E) ratio of 132.50.

    What is ICCC's market cap?

    ImmuCell Corporation (ICCC) has a market capitalization of $97.63M with a current stock price of $10.56.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In